The Tire Lawyers | June 20, 2020
As global tire manufacturing ramps back up after COVID-19 pandemic closings, trial lawyers at Kaster, Lynch, Farrar & Ball (KLF&B) are calling on the industry to be vigilant about quality control and urging regulators and consumers to be on the lookout for defective tires entering the market.
Tire manufacturing depends on precise temperature and humidity settings that affect chemical reactions, as well as complex mechanical adjustments, and any changes in those variables can result in dangerous tread defects, said trial lawyer Wes Ball.
"Tire manufacturing is a complicated process with no room for error," said Mr. Ball. "These companies have learned that government oversight only goes so far. We fight to hold them accountable when they fail to keep dangerous products out of the marketplace."
businesswire | January 11, 2021
Baxter International Inc, a worldwide pioneer in clean medicine creation and conveyance, today declared that Baxter BioPharma Solutions has gone into a consent to give clean assembling administrations to NVX-CoV2373, Novavax' COVID-19 recombinant nanoparticle immunization applicant with Matrix-M™ adjuvant. Baxter BioPharma Solutions is a head contract fabricating association that works in parenteral (injectable) drugs, including antibodies. The understanding is required to propel business scale fabricating basic for the immunization's creation and appropriation in the United Kingdom and European business sectors. Novavax' COVID-19 antibody applicant is at present in stage 3 preliminaries and has not yet been approved or affirmed for use.
“The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all,” said Marie Keeley, vice president, Baxter BioPharma Solutions. “We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market.”
As per Novavax, NVX-CoV2373 contains a full-length, prefusion spike protein made utilizing Novavax' recombinant nanoparticle innovation and the organization's restrictive saponin-based Matrix-M™ adjuvant. The cleaned protein is encoded by the hereditary arrangement of the SARS-CoV-2 spike (S) protein and is created in creepy crawly cells. It can neither reason COVID-19 sickness nor would it be able to reproduce, is steady at 2°C to 8°C and is made in a prepared to-utilize fluid definition that grants circulation utilizing standard immunization production network channels.
“Our priority is to bring a safe, effective COVID-19 vaccine to people around the world,” said Rick Crowley, executive vice president, chief operations officer, Novavax. “Partners like Baxter BioPharma Solutions are enabling Novavax to quickly establish a commercial supply chain network to ensure access for global populations, and ultimately help bring about an end to the global COVID-19 pandemic.”
Baxter's assembling administrations for NVX-CoV2373 will happen at its cutting edge office in Halle/Westfalen, Germany. The site has wide sterile assembling capacities and regions of center, offers current great assembling rehearses (cGMP) fabricating with committed creation zones and is intended to convey items with ideal proficiency and speed to advertise. Baxter's as of late extended Halle/Westfalen office has been in activity for over 60 years.
About Baxter's BioPharma Solutions Business
Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems and customized support services needed to meet the unique challenges that parenteral products face.
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
LG Energy Solutions | December 14, 2021
LG Energy Solution (LGES), a leading global battery maker announced Tuesday that it has signed a Memorandum of Understanding (MoU) with a German-based technology company Siemens Aktiengesellschaft (Siemens AG) for joint collaboration in the field of battery manufacturing, particularly the digitization of production process.
Under the terms of the agreement, which was signed by Young Soo Kwon, CEO of LG Energy Solution and Cedrik Neike, Member of the Managing Board of Siemens AG and CEO Digital Industries at LGES's headquarters in Seoul Monday, the two companies plan to take steps to promote the process of battery manufacturing intelligence at LGES production facilities worldwide.
Through this strategic collaboration, LGES will be able to implement smart battery manufacturing processes at its factories with the advanced techniques. The partnerships' first line of collaboration will be realized at Ultium Cells LLC, a joint venture of LG Energy Solution and General Motors, located in Tennessee, which is expected to begin production in 2023.
Furthermore, the collaboration will allow LGES to cut back on Carbon footprint in its entire supply chain management, as it aims to boost sustainability in its business operations. LGES previously announced its ESG visions and business strategies to embrace sustainable business practices.
As a leading supplier in the field of automation, industrial software, Siemens AG offers comprehensive digital enterprise portfolio and domain knowledge in the battery industry for LGES to accelerate efficiencies for digital transformation strategy.
In addition, Siemens AG will contribute to the development of the rapid growing battery industry by solidifying its position as a technology partner for the advancement and efficiency of battery manufacturing technology.
Two companies will also collaborate on building digital twin roadmap to ensure stable operations at facilities to offer first-rate quality products at the right time. Together, the companies will also develop training programs within Institute of Battery Technology (IBT) for academic students set to work for LGES. LG Energy Solution previously announced it will build IBT in Korea to educate and build expertise in battery technologies.
We believe the partnership with the world-renown Siemens AG will efficiently promote LG Energy Solution's digitized manufacturing processes, ultimately enabling LGES to provide the finest services to our clients. The process of manufacturing intelligence in producing batteries is becoming a critical factor, especially as LGES continues to advance the quality of its products while expanding production base worldwide."
Young Soo Kwon, CEO of LG Energy Solution
About LG Energy Solution
LG Energy Solution is a global leader delivering advanced lithium-ion batteries for Electric Vehicles (EV), Mobility & IT applications, and Energy Storage Systems (ESS). With 30 years of experience in advanced battery technology, it continues to grow rapidly towards the realization of sustainable life. With its robust global network that spans the US, Europe, Asia, and Australia, LG Energy Solution is more committed than ever to developing innovative technologies that will bring the future energy a step closer. Under its ESG vision "We CHARGE toward a better future," LG Energy Solution is doing its utmost to prioritize environment, fulfil social responsibilities and shape sustainable future.
Siemens AG (Berlin and Munich) is a technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In addition, Siemens holds a minority stake in Siemens Energy, a global leader in the transmission and generation of electrical power. In fiscal 2021, which ended on September 30, 2021, the Siemens Group generated revenue of €62.3 billion and net income of €6.7 billion. As of September 30, 2021, the company had around 303,000 employees worldwide.
Siemens Digital Industries (DI) is a leading innovator in automation and digitalization. In close cooperation with its partners and customers, DI is the driving force for the digital transformation in the process and manufacturing industries. With its Digital Enterprise portfolio, Siemens provides companies of all sizes with all the necessary products, along with consistent solutions and services for the integration and digitalization of the entire value chain. Optimized for the specific requirements of individual industries, this unique portfolio enables customers to enhance their productivity and flexibility. DI continuously extends its portfolio to include innovations and the integration of future-oriented technologies. Siemens Digital Industries, with its headquarters in Nuremberg, has a workforce of around 76,000 employees worldwide.